mutations presented the fact that, as spelled out underneath, CLL therapy is predicated within the presence or absence of these mutations. The existing consensus is that, other than clonal mutations, subclonal mutations which has a variant allelic frequency starting from 5 to 10% (and so down below the edge of detection by common molecular techniqu